BD Completing Its Planned Spinoff of Diabetes Subsidiary Embecta

Becton Dickinson (BD) has announced that it expects the spinoff of its diabetes care subsidiary Embecta to be completed on April 1.

Embecta, which supplies insulin pens and syringes, will be “one of the largest pure-play diabetes management companies in the world,” with approximately 2,000 employees in various countries, BD said.

BD reported $156 million in revenue from diabetes care products for fiscal year 2021, which ended Sept. 30, up by 7.6 percent from the previous year.